We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Roche Constructs Diagnostics Facility Near Munich

By LabMedica International staff writers
Posted on 06 Oct 2008
Roche (Basel, Switzerland) is investing US$190 million at its site in Penzberg, near Munich, Germany. More...
The money will be used to construct a multi-purpose building for Roche Diagnostics. The new building will be known as the Diagnostics Operations Complex (DOC) and will have a total floor area of 30,400 square meters. The complex consists of a central six-storied laboratory building with a basement flanked by two single-storied factory halls for the production units.

The building will house laboratories and production facilities for the Roche Applied Science and Roche Professional Diagnostics business areas. From about the middle of 2010, the complex will be manufacturing products ranging from biotech constituents for immunodiagnostics and the life-science market through to complete immunodiagnostic test kits. These test kits are used worldwide in diagnostic systems such as Cobas and Elecsys.

One of Roche's important markets is immunodiagnostics, which includes heterogeneous tests such as the cardiac markers NT-proBNP for acute and chronic heart failure and troponin T for myocardial infarction. Roche's immunologic tests are used by physicians for a variety of other applications, such as checking thyroid function, determining tumor markers, detecting infectious diseases such as hepatitis and human immunodeficiency virus (HIV), or helping to verify the effectiveness of drug-based therapy.

"In recent years, we have been successful in continuously expanding and marketing our range of immunodiagnostic tests,” said Jürgen Schwiezer, CEO of Roche's Diagnostics Division. "We are systematically pushing forward our activities in this interesting growth market by strengthening our capacity and capabilities in the research, development, and production of diagnostics constituents and tests. Against this background, the investment marks an important step in enhancing our leading position in the immunodiagnostics segment.”

Roche is an innovator of products and services for the prevention, early detection, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and a market leader in virology.

Related Links:
Roche


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
POC Immunoassay Analyzer
Procise DX
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.